Literature DB >> 4023710

Antibody-directed urokinase: a specific fibrinolytic agent.

C Bode, G R Matsueda, K Y Hui, E Haber.   

Abstract

A specific fibrinolytic agent was synthesized by covalently coupling urokinase to a monoclonal antibody that was fibrin-specific and did not cross-react with fibrinogen. The antibody was raised against a synthetic peptide representing the seven amino-terminal residues of the beta chain of human fibrin. The urokinase-antifibrin conjugate retained the original binding specificity of the antibody and showed 100-fold increased fibrinolysis in vitro when compared to unmodified urokinase. The presence of human fibrinogen at plasma concentration did not influence these properties.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4023710     DOI: 10.1126/science.4023710

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  19 in total

Review 1.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

2.  Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.

Authors:  M S Runge; C Bode; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 3.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

Review 4.  Monoclonal antibodies as magic bullets.

Authors:  F M Brodsky
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

5.  Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Kristina Danielyan; Juan-Carlos Murciano; Kumkum Ganguly; Tatiana Krasik; Ronald P Taylor; Steven Pincus; Steven Jones; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

Review 6.  Thrombolysis. An approach still on the move.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

7.  Reagents for reversible coupling of proteins to the active centres of trypsin-like serine proteinases.

Authors:  S B Kalindjian; R A Smith
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

8.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Claudia Gottstein; Andrea Grunow; Alice Kuo; Kumkum Ganguly; Steven M Albelda; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

9.  Selective cytotoxicity of an oxygen-radical-generating enzyme conjugated to a monoclonal antibody.

Authors:  M G Battelli; A Abbondanza; P L Tazzari; A Dinota; S Rizzi; G Grassi; M Gobbi; F Stirpe
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

Review 10.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.